Zoetis Inc. (ZTS)
Summary
Zoetis: A Solid Long-Term Buy After Harsh Drawdown
Zoetis is navigating the worst drawdown in its stock history, driven by weakening U.S. vet clinic traffic and heightened competition across key companion animal franchises. Despite aggressive competitor promotions, Zoetis protects industry-leading profitability (35%–37% EBIT margins) using targeted gross-to-net rebates rather than base list-price cuts. Trading at a historic low 12x P/E and a 7%+ FCF yield, Zoetis offers a strong margin of safety compared to its Base Case DCF fair value of $100.06.
Zoetis: Another Bad Quarter, Some Value Trap Risk But Shares Still Cheap
Zoetis' Q2 earnings results were mixed, and the company cut its forward guidance. This has reduced the stock's margin of safety, but on balance, the risk/reward profile still favors the bulls. Zoetis has other segments performing well which partially offset the weakness in U.S. pet-related sales.
Zoetis: The Growth Story Has Broken, But The Valuation Finally Makes Sense
Zoetis (ZTS) now trades at just 12x forward earnings, with a nearly 3% dividend yield and gross margins above 70%, after a severe multiyear drawdown. Competition, weaker U.S. companion animal sales, and reduced guidance have pressured ZTS, but its core profitability and market dominance remain intact. Management is aggressively repurchasing shares, capital returns are strong, and the balance sheet remains healthy despite $9B in long-term debt.
Zoetis Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TJD Thomas John Drogan PR Inc.IPAL SECURITIES Inc. | 24,523 | $3.22M | $1.86M | -$1.35M | -42.11% |
| DI David Izzi Brown, LISLE/CUMMINGS Inc. | 1,525 | $313,143.18 | $117,867.25 | -$195,275.93 | -62.36% |
 Timothy M. Bidwell Hazlett, BURT & WATSON Inc. | 299 | $46,980.34 | $23,109.71 | -$23,870.63 | -50.81% |
| LC Lisa Candera CIGNA INVESTMENTS Inc. /NEW | 3,959 | $552,759.78 | $305,991.11 | -$246,768.67 | -44.64% |
 Curtis Ellergodt Rothschild Investment LLC | 2,182 | $408,602.26 | $165,919.28 | -$242,682.98 | -59.39% |
Zoetis Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| SS Steve Scala TD Cowen | 424.01 | $30,469.51 | $32,882.14 | $2,412.63 | 7.92% |
 Rajesh Kumar HSBC | 372.58 | $28,099.68 | $28,893.26 | $793.58 | 2.82% |
| NT Navann Ty BNP Paribas | 1,537.05 | $115,017.22 | $115,816.48 | $799.26 | 0.69% |
Zoetis Inc. (ZTS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Zoetis Inc. ever had a stock split?
Zoetis Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Kristin C. Peck CEO | NYSE Exchange | 98978V103 CUSIP |
| US Country | 14,500 Employees | 20 Jul 2026 Last Dividend | - Last Split | 1 Feb 2013 IPO Date |
Overview
Zoetis Inc. is a global leader in the discovery, development, manufacture, and commercialization of a wide range of animal health medicines, vaccines, and diagnostic products. Founded in 1952 and based in Parsippany, New Jersey, the company addresses the health needs of both livestock—including cattle, swine, poultry, fish, and sheep—and companion animals, such as dogs, cats, and horses. With a presence in both the United States and international markets, Zoetis delivers products and services designed to meet the complex challenges of animal health, ensuring the well-being of animals across the globe. The company's extensive product line-up, alongside innovative diagnostic solutions, makes it a vital player in promoting animal health and supporting the veterinarians, livestock producers, and pet owners who care for them.
Products and Services
Zoetis Inc. offers an expansive portfolio of products and services designed to enhance animal health and support the professionals who work with animals. These include:
- Vaccines: Zoetis provides biological preparations that protect against diseases of the respiratory, gastrointestinal, and reproductive tracts. These vaccines induce a specific immune response in a variety of animals, helping prevent outbreaks and the spread of infectious diseases in both livestock and companion animals.
- Anti-infectives: These products are formulated to prevent, kill, or slow the growth of harmful bacteria, fungi, or protozoa. By offering a range of anti-infectives, Zoetis contributes to the overall health and well-being of animals, helping to combat infections before they become widespread issues.
- Parasiticides: To protect animals from external and internal parasites, Zoetis commercializes treatments that eliminate or prevent infestations such as fleas, ticks, and worms. These products are critical in maintaining animal health and preventing the transmission of parasite-borne diseases to other animals and humans.
- Other Pharmaceutical Products: Beyond vaccines and parasiticides, Zoetis offers a variety of pharmaceutical products addressing pain and sedation, antiemetic therapies, reproductive health, and oncology in animals. Additionally, the company provides dermatology products for conditions such as allergic dermatitis, ensuring comprehensive care for a wide range of health needs.
- Medicated Feed Additives: These products mix medicines with livestock feed to prevent or treat disease and enhance overall animal health. Medicated feed additives are a critical component in the maintenance of healthy commercial herds and flocks.
- Diagnostic Products: Zoetis delivers a variety of diagnostic solutions, including portable blood and urine analysis testing kits, point-of-care products, and instruments. These diagnostic tools are vital for early detection of disease and condition management in animal healthcare settings.
- Non-Pharmaceutical Products and Services: In addition to its pharmaceutical offerings, Zoetis provides nutritionals and agribusiness services, products for biodevices, genetic tests, and precision animal health solutions. These products and services support the broader aspects of animal care and health management.
